Vera Therapeutics, Inc. (VERA)Healthcare | Biotechnology | Brisbane, United States | NasdaqGM
26.74 USD
-0.05
(-0.187%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:30 a.m. EDT
The investment case for Vera Therapeutics is currently fractured by a stark disconnect between optimistic analyst targets and deteriorating operational reality. While analysts project a mean price of $77.50, the company is burning through cash at a rapid pace with negative free cash flow and no revenue, resulting in a negative return on equity and assets. This fundamental weakness is reflected in the price action, which has failed to sustain its massive 185% run-up and is now trading significantly below its moving averages. The options market confirms this skepticism, with traders aggressively stacking downside protection via deep out-of-the-money puts, signaling a fear of further correction rather than a belief in an imminent recovery. Without a clear path to profitability or a catalyst that can reverse the multi-year trend of value destruction, the risk-reward profile remains skewed toward caution. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.051567 |
| AutoETS | 0.051567 |
| AutoTheta | 0.051579 |
| MSTL | 0.051937 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.32 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.504 |
| Excess Kurtosis | -0.75 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.86 |
| Market Cap | 1,926,973,568 |
| Forward P/E | -6.28 |
| Beta | 1.05 |
| Website | https://veratx.com |
As of Oct. 10, 2026, 4:30 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in out-of-the-money puts (over 15,000 contracts at the $35 strike for Jan '27 expiration) compared to negligible call volume. While there is some speculative call activity at distant strikes ($60), the overwhelming capital allocation is in put writing and buying, suggesting a consensus view of continued volatility and potential further declines rather than a breakout rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.12192726 |
| Address1 | 2,000 Sierra Point Parkway |
| Address2 | Suite 1200 |
| All Time High | 56.05 |
| All Time Low | 5.2 |
| Ask | 38.91 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,994,380 |
| Average Daily Volume3 Month | 2,172,441 |
| Average Volume | 2,172,441 |
| Average Volume10Days | 1,994,380 |
| Beta | 1.052 |
| Bid | 22.14 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 5.667 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.74 |
| Current Ratio | 10.916 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 27.42 |
| Day Low | 26.375 |
| Debt To Equity | 18.86 |
| Display Name | Vera Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -415,224,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.624 |
| Enterprise Value | 1,504,717,568 |
| Eps Current Year | -6.25401 |
| Eps Forward | -4.25911 |
| Eps Trailing Twelve Months | -5.87 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 32.4775 |
| Fifty Day Average Change | -5.737501 |
| Fifty Day Average Change Percent | -0.17666079 |
| Fifty Two Week Change Percent | -12.192726 |
| Fifty Two Week High | 56.05 |
| Fifty Two Week High Change | -29.31 |
| Fifty Two Week High Change Percent | -0.522926 |
| Fifty Two Week Low | 23.05 |
| Fifty Two Week Low Change | 3.6900005 |
| Fifty Two Week Low Change Percent | 0.1600868 |
| Fifty Two Week Range | 23.05 - 56.05 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,620,999,000,000 |
| Float Shares | 52,389,324 |
| Forward Eps | -4.25911 |
| Forward P E | -6.278307 |
| Free Cashflow | -212,947,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 361 |
| Fullday Change | 0.21999931 |
| Fullday Change Percent | 0.8227349 |
| Fullday Price | 26.96 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01013 |
| Held Percent Institutions | 1.18121 |
| Implied Shares Outstanding | 72,063,335 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-05-14 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. |
| Long Name | Vera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,926,973,568 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_683328925 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -401,895,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,381,693,221 |
| Number Of Analyst Opinions | 15 |
| Open | 26.67 |
| Operating Cashflow | -338,652,992 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Phone | 650 770 0077 |
| Pre Market Change | 0.21999931 |
| Pre Market Change Percent | 0.8227349 |
| Pre Market Price | 26.96 |
| Pre Market Time | 1,792,052,356 |
| Previous Close | 26.79 |
| Price Eps Current Year | -4.2756567 |
| Price Hint | 2 |
| Price To Book | 4.718546 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.411 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.050001144 |
| Regular Market Change Percent | -0.18664107 |
| Regular Market Day High | 27.42 |
| Regular Market Day Low | 26.375 |
| Regular Market Day Range | 26.375 - 27.42 |
| Regular Market Open | 26.67 |
| Regular Market Previous Close | 26.79 |
| Regular Market Price | 26.74 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 1,534,552 |
| Return On Assets | -0.46756 |
| Return On Equity | -0.91753 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 72,063,335 |
| Shares Percent Shares Out | 0.2392 |
| Shares Short | 17,240,397 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 19,873,297 |
| Short Name | Vera Therapeutics, Inc. |
| Short Percent Of Float | 0.2723 |
| Short Ratio | 6.93 |
| Source Interval | 15 |
| State | CA |
| Symbol | VERA |
| Target High Price | 100.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 74.2 |
| Target Median Price | 80.0 |
| Total Cash | 499,160,992 |
| Total Cash Per Share | 6.927 |
| Total Debt | 76,905,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.87 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 38.244274 |
| Two Hundred Day Average Change | -11.504274 |
| Two Hundred Day Average Change Percent | -0.30081037 |
| Type Disp | Equity |
| Volume | 1,534,552 |
| Website | https://veratx.com |
| Zip | 94,005 |